DRUG ELUTING BALLOON MARKET ANALYSIS

Drug Eluting Balloon Market Size and Trends

Global drug eluting balloon market is estimated to be valued at USD 713.9 Mn in 2024 and is expected to reach USD 1,271.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.6% from 2024 to 2031.

To learn more about this report, request sample copy

Global drug eluting balloon market has witnessed significant growth, owing to rising prevalence of cardiovascular diseases worldwide. As per estimates, cardiovascular diseases account for over 17.9 million deaths globally every year. Factors such as growing geriatric population, increasing obesity rates, and changing lifestyle habits increases the risk of cardiovascular diseases, and this  boosts demand for drug eluting balloons as a safer minimally invasive treatment alternative to stenting. Ongoing advancements in balloon material and drug coating technologies drives the market growth by introducing newer and more effective products with enhanced vessel healing, antiesthetic, and anti-proliferative properties.

Market Driver – Increasing Product Launches by Key Market Players

Market players are engaged in launching new drugs, and this is expected to drive growth of the global drug eluting balloon market over the forecast period. For instance, in July 2021, Med Alliance SA, a medical technology company, launched ORIGIN SC and ORIGIN NC, two high performance drug eluting balloons for vessel preparation. These complement SELUTION SLR, its novel sirolimus-eluting balloon. ORIGIN SC is a semi-compliant (SC) PTCA balloon with a very low crossing profile, thus, making it an excellent choice for challenging lesions. ORIGIN SC offers one of the broadest portfolios of sizes available for an semi-compliant (SC) balloon, including 1.00 mm, 1.25 mm, 1.50 mm and 1.75 mm balloon diameters to treat very small vessels and complex cases. ORIGIN NC is a non-compliant (NC) PTCA balloon, combining high pressure tolerance and controlled compliance with an optimal crossing profile for the most challenging cases.

Increasing prevalence of cardiovascular diseases across the globe is expected to drive the growth of the drug eluting balloon market. World Health Organization, cardiovascular diseases account for over 17.9 million deaths each year globally. Some of the major cardiovascular conditions include coronary heart disease, stroke and peripheral arterial disease. Aging populations, changing environmental factors and genetic predispositions  further contribute to rising disease burden. Drug eluting balloons are being increasingly used by physicians for treating peripheral arterial diseases affecting the hips and legs as well as coronary artery diseases impacting the heart. These prevent vessel recoil and neointimal hyperplasia after angioplasty procedures through the controlled, localized delivery of anti-proliferative drugs to damaged vessel sites. This minimizes the risk of restenosis and the need for additional revascularization treatments. Recent clinical studies have demonstrated drug eluting balloons to be as effective as drug eluting stents in addressing various types of atherosclerotic lesions with fewer safety issues.